18:54 , Jun 19, 2019 |  BC Extra  |  Financial News

June 19 Financial Quick Takes: Stoke rises after IPO; plus Polaris, Woodford, follow-ons

Stoke catches fire after pricing upsized IPO  Genetic diseases company Stoke Therapeutics Inc. (NASDAQ:STOK) gained $7.57 (42%) to $25.57 in its first day of trading Wednesday after raising $142 million in its IPO. The company...
23:32 , Apr 30, 2019 |  BC Extra  |  Financial News

April 30 Financial Quick Takes: Mustang, Tot Biopharm, Axcella and more

Mustang raises $27.5M after gene therapy data Mustang Bio Inc. (NASDAQ:MBIO) raised $27.5 million in a follow-on underwritten by Cantor Fitzgerald, Oppenheimer, H.C. Wainwright and Roth Capital. The offering comes on the heels of positive...
14:23 , Mar 20, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Dermira, resTORbio, NanoString

Dermira raised $130 million in an upsized offering that followed closely after its eczema readout this week, while resTORbio and NanoString also priced follow-ons late Tuesday. Dermira Inc. (NASDAQ:DERM) sold 9.8 million shares at $13.25,...
17:37 , Mar 18, 2019 |  BC Extra  |  Clinical News

Dermira jumps on Phase IIb atopic dermatitis readout

Dermira added $5.77 (84%) to $12.61 on Monday after reporting that all three doses of lebrikizumab met the primary endpoint in a Phase IIb trial to treat adults with moderate-to-severe atopic dermatitis. Dermira Inc. (NASDAQ:DERM)...
17:32 , Mar 8, 2019 |  BC Week In Review  |  Financial News

TG raises $55.2M in debt and equity financings

Cancer and autoimmune company TG Therapeutics raised $25.2 million in a follow-on underwritten by Cantor Fitzgerald through the sale of 4.1 million shares at $5.87. The price is a 13% premium to the company's close...
21:51 , Mar 7, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
23:30 , Mar 6, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Ascendis, Sarepta

Ascendis and Sarepta each priced follow-ons, raising $500 million and $375 million, respectively, after the bell Tuesday. Invitae and CymaBay also priced follow-ons. Ascendis Pharma A/S (NASDAQ:ASND) raised $500 million through the sale of 4.2...
21:05 , Mar 4, 2019 |  BC Extra  |  Clinical News

Ascendis jumps on Phase III readout for once-weekly growth hormone

Ascendis gained $51.29 (74%) to $120.60 on Monday after reporting that its TransCon Growth Hormone met the primary endpoint in the Phase III heiGHt trial to treat pediatric growth hormone deficiency. The company plans to...
18:25 , Feb 28, 2019 |  BC Extra  |  Clinical News

TG aims for accelerated approval of lymphoma candidate

TG Therapeutics Inc. (NASDAQ:TGTX) added $1.61 (31%) to $6.80 on Thursday after reporting that umbralisib (TGR-1202) met the primary endpoint in a cohort of marginal zone lymphoma patients in a pivotal Phase IIb trial. The...
20:41 , Jan 18, 2019 |  BC Week In Review  |  Financial News

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch. Acceleron said Jan. 16 that...